[{"id":"fd928f04-9fea-4aed-9d3c-1bbb9efc47b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01673477","created_at":"2021-01-18T07:14:33.837Z","updated_at":"2024-07-02T16:37:18.467Z","phase":"Phase 1","brief_title":"Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer","source_id_and_acronym":"NCT01673477","lead_sponsor":"EGEN, Inc.","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pegylated liposomal doxorubicin • IMNN-001 • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2017-08-25"}]